CLEARWATER, Fla.--(BUSINESS WIRE)--Bovie Medical Corporation (“Bovie or the “Company”) (NYSE:BVX), a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, announced today that it has named Jay Ewers to the position of Chief Financial Officer.
Mr. Ewers has served as interim CFO since mid-June of this year and was previously the Company’s Corporate Controller. He has more than 30 years of senior experience, having held financial executive positions in corporations ranging from early stage to high profile public companies with global operations in the medical equipment, manufacturing and semiconductor industries.
Commenting on the appointment, Robert L. Gershon, Chief Executive Officer said, “Jay’s performance in the role of interim CFO over these last three months has been outstanding, and it is with great pleasure that we announce his promotion to CFO. Jay has impressed our Board, our executives and staff members and our investors by his hands-on experience in financial planning management, internal controls and his grasp of the infrastructure we need to support future growth.”
Mr. Ewers noted, “I am pleased to take on permanent CFO responsibilities at Bovie during this exciting time in the Company’s history, when adoption of our J-Plasma® product continues to build in targeted and new specialties, and we add new products to our core business portfolio.”
Mr. Ewers is a certified public accountant, a certified internal auditor, and holds a BS in Accounting.
About Bovie Medical Corporation
Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation’s website www.boviemed.com
Cautionary Statement on Forward-Looking Statements
Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.
Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this release can be found in the Company’s filings with the Securities and Exchange Commission including the Company’s Report on Forms 10-Q for the quarters ended June 30, 2015, and March 31, 2015 respectively. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.